Sagimet Showcases Denifanstat at MASH Summit for Liver Health
Sagimet Highlights Denifanstat's Potential at MASH Summit
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company, focuses on innovating treatments for metabolic disorders through its development of fatty acid synthase (FASN) inhibitors aimed at dysfunctional metabolic and fibrotic pathways. Recently, Sagimet announced an exciting opportunity to present its findings on denifanstat, particularly its anti-fibrotic activity in metabolic dysfunction-associated steatohepatitis (MASH). This presentation will occur during the 8th Annual MASH Drug Development Summit, a renowned event dedicated to advancing research in liver diseases.
Details of the Presentation at the MASH Summit
The upcoming presentation is poised to contribute significantly to the understanding of denifanstat’s role in treating MASH. Here are the essential details:
Presentation Title
Demonstrating denifanstat’s differentiated approach in MASH with mechanistic and clinical data showing direct anti-fibrotic activity.
Presenter Information
The presentation will be led by Marie O’Farrell, Ph.D., who serves as the Senior Vice President of Research and Development at Sagimet Biosciences.
Session Overview
This session, titled "Showcasing Antifibrotic Progress, Past Learnings & Innovations to Supercharge MASH Drug Development," aims to highlight the advancements in the field and spark conversations about future treatment possibilities.
Date and Timing
The oral presentation is scheduled for Thursday, September 26, from 4:15 PM to 4:45 PM ET.
About Sagimet and Denifanstat
Sagimet is paving the way for innovative treatments through its lead drug candidate, denifanstat. This medication is a selective FASN inhibitor, administered as an oral, once-daily pill intended to manage MASH effectively. Recent research, particularly the FASCINATE-2 trial, has yielded promising results, further establishing denifanstat’s potential in reversing the effects of MASH, which is a significant concern in public health worldwide.
Understanding MASH: A Global Health Challenge
MASH is a serious form of liver disease affecting millions of individuals globally. It is linked to the accumulation of fat in the liver and can lead to severe health outcomes if not treated effectively. Despite the impact it has on over 115 million people, treatment options remain limited, with only a single drug approved recently in the United States and none in Europe. This landscape is slowly changing as medical societies work to enhance the understanding and terminology associated with these liver conditions.
In 2023, significant changes in terminology occurred, where non-alcoholic fatty liver disease (NAFLD) was renamed to metabolic dysfunction-associated steatotic liver disease (MASLD). Similarly, nonalcoholic steatohepatitis (NASH) is now referred to as MASH, marking an effort to destigmatize and better classify these liver ailments. This progressive move aims to promote awareness and understanding of the implications surrounding liver health.
Contact and Further Information
For anyone seeking more information about Sagimet and its trailblazing work in liver health, inquiries can be directed to:
Joyce Allaire
LifeSci Advisors
Email: Jallaire@lifesciadvisors.com
Frequently Asked Questions
What is denifanstat, and why is it significant?
Denifanstat is a selective fatty acid synthase (FASN) inhibitor being developed by Sagimet to treat MASH, which is crucial given the disease's severe implications for liver health.
Where and when will the MASH presentation take place?
The oral presentation showcasing denifanstat's findings will be held at the MASH Drug Development Summit on September 26, from 4:15 PM to 4:45 PM ET.
What recent changes have been made to liver disease terminology?
In 2023, NAFLD was renamed to MASLD, and NASH is now referred to as MASH, aiming to provide a clearer understanding of these diseases.
How many people are affected by MASH globally?
MASH has a significant impact, affecting more than 115 million people worldwide, highlighting the need for effective treatments.
What makes the MASH Summit an essential event?
The MASH Summit serves as a platform for researchers and practitioners to share innovations, learnings, and advancements, vital for combating liver diseases effectively.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.